SCHEMBL10246744

SCHEMBL10246744

CC(C)(C)OC(=O)COCc1cccc(/C(N)=N\O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.39
PLA2G4B P0C869 1/20 0.39
KDM1A O60341 2/20 0.39
RAB9A P51151 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MRGPRX4 Q96LA9 4/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
BMP1 P13497 1/20 0.35
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9968919 0.88 SLC7A5 (0.40) SLC7A5L3MBTL1KDM1ARAB9ATDP1
SCHEMBL10246740 0.88 SLC7A5 (0.40) SLC7A5L3MBTL1PLA2G4BKDM1ARAB9A
SCHEMBL406656 0.88 SLC7A5 (0.40) SLC7A5L3MBTL1PLA2G4BKDM1ARAB9A
SCHEMBL406657 0.88 SLC7A5 (0.40) SLC7A5L3MBTL1PLA2G4BKDM1ARAB9A
SCHEMBL10249347 0.85 RAB9A (0.38) L3MBTL1PLA2G4BKDM1ARAB9AALDH1A1
SCHEMBL3420016 0.82 L3MBTL1 (0.50) SLC7A5L3MBTL1KDM1ARAB9ATDP1
SCHEMBL408725 0.82 KDM1A (0.43) L3MBTL1PLA2G4BKDM1ARAB9ATDP1
SCHEMBL408726 0.82 KDM1A (0.43) L3MBTL1PLA2G4BKDM1ARAB9ATDP1
SCHEMBL9968906 0.79 SLC7A5 (0.40) SLC7A5L3MBTL1KDM1ARAB9ATDP1
SCHEMBL13145859 0.78 SLC7A5 (0.42) SLC7A5L3MBTL1RAB9ATDP1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 EP disclosed
US-8815919-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2014-08-26 US disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 US disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 US disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB SLC7A5 2990/4885L3MBTL1 4637/4885PLA2G4B 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.